OnKure Therapeutics reprices about 1.7 million underwater stock options to $4.14
On August 7, 2026, OnKure Therapeutics' board approved a repricing of employee and consultant stock options with exercise prices of $10.00 or more, including options held by its named executive officers. The repriced options now carry a $4.14 exercise price, the August 7 closing price, and the filing says the company made no change to expiration dates, vesting or share counts; it states the change was meant to retain staff without new equity grants or added cash pay.
Key points
- Effective date of August 7, 2026; new exercise price of $4.14 per share, the closing price that day
- About 1.7 million shares underlie repriced options, roughly 40% of outstanding options had exercise prices above the $10.00 threshold
- CEO Nicholas A. Saccomano holds 571,423 repriced option shares; CMO Samuel Agresta holds 149,984; CFO Jason Leverone holds 141,714
- Optionees must stay in service 18 months (senior management, including named executive officers) or one year (other staff), or pay the original higher exercise price
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.